ANIK Anika Therapeutics Inc

Price (delayed)

$22.5

Market cap

$327.24M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.11

Enterprise value

$255.73M

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need ...

Highlights
Anika Therapeutics's quick ratio has soared by 72% YoY and by 6% from the previous quarter
The company's gross profit rose by 22% YoY
The net income has dropped by 140% since the previous quarter but it has surged by 94% year-on-year
The company's EPS has shrunk by 138% QoQ but it has surged by 94% YoY

Key stats

What are the main financial stats of ANIK
Market
Shares outstanding
14.54M
Market cap
$327.24M
Enterprise value
$255.73M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.14
Price to sales (P/S)
2.17
EV/EBIT
N/A
EV/EBITDA
18.62
EV/Sales
1.7
Earnings
Revenue
$150.2M
EBIT
-$2.4M
EBITDA
$13.73M
Free cash flow
$2.91M
Per share
EPS
-$0.11
Free cash flow per share
$0.2
Book value per share
$19.75
Revenue per share
$10.38
TBVPS
$17.57
Balance sheet
Total assets
$342.24M
Total liabilities
$56.45M
Debt
$18.82M
Equity
$285.79M
Working capital
$138.33M
Liquidity
Debt to equity
0.07
Current ratio
6.12
Quick ratio
4.43
Net debt/EBITDA
-5.21
Margins
EBITDA margin
9.1%
Gross margin
55.8%
Net margin
-1.1%
Operating margin
-12.3%
Efficiency
Return on assets
-0.5%
Return on equity
-0.6%
Return on invested capital
-1.6%
Return on capital employed
-0.8%
Return on sales
-1.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIK stock price

How has the Anika Therapeutics stock price performed over time
Intraday
-4.26%
1 week
1.9%
1 month
6.99%
1 year
-49.7%
YTD
-37.2%
QTD
-10.39%

Financial performance

How have Anika Therapeutics's revenue and profit performed over time
Revenue
$150.2M
Gross profit
$83.77M
Operating income
-$18.47M
Net income
-$1.64M
Gross margin
55.8%
Net margin
-1.1%
The net income has dropped by 140% since the previous quarter but it has surged by 94% year-on-year
Anika Therapeutics's net margin has shrunk by 139% QoQ but it has surged by 95% YoY
Anika Therapeutics's operating margin has soared by 63% YoY
Anika Therapeutics's operating income has soared by 57% YoY

Growth

What is Anika Therapeutics's growth rate over time

Valuation

What is Anika Therapeutics stock price valuation
P/E
N/A
P/B
1.14
P/S
2.17
EV/EBIT
N/A
EV/EBITDA
18.62
EV/Sales
1.7
The company's EPS has shrunk by 138% QoQ but it has surged by 94% YoY
ANIK's price to book (P/B) is 46% less than its 5-year quarterly average of 2.2 and 34% less than its last 4 quarters average of 1.8
ANIK's equity is up by 3.3% year-on-year
ANIK's P/S is 55% below its 5-year quarterly average of 5.0 and 39% below its last 4 quarters average of 3.7
The revenue has grown by 16% YoY

Efficiency

How efficient is Anika Therapeutics business performance
The ROIC has dropped by 194% since the previous quarter but it has soared by 91% year-on-year
The company's return on sales has shrunk by 189% QoQ but it has surged by 94% YoY
Anika Therapeutics's ROE has plunged by 143% from the previous quarter but it has soared by 94% YoY
The return on assets has dropped by 142% since the previous quarter but it has surged by 93% year-on-year

Dividends

What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIK.

Financial health

How did Anika Therapeutics financials performed over time
Anika Therapeutics's quick ratio has soared by 72% YoY and by 6% from the previous quarter
Anika Therapeutics's current ratio has soared by 66% YoY and by 8% from the previous quarter
Anika Therapeutics's debt is 93% lower than its equity
Anika Therapeutics's debt has decreased by 8% YoY and by 2.2% QoQ
ANIK's equity is up by 3.3% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.